跳轉至內容
Merck
  • Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Cancer cell (2008-05-06)
Sonia Lain, Jonathan J Hollick, Johanna Campbell, Oliver D Staples, Maureen Higgins, Mustapha Aoubala, Anna McCarthy, Virginia Appleyard, Karen E Murray, Lee Baker, Alastair Thompson, Joanne Mathers, Stephen J Holland, Michael J R Stark, Georgia Pass, Julie Woods, David P Lane, Nicholas J Westwood
摘要

We have carried out a cell-based screen aimed at discovering small molecules that activate p53 and have the potential to decrease tumor growth. Here, we describe one of our hit compounds, tenovin-1, along with a more water-soluble analog, tenovin-6. Via a yeast genetic screen, biochemical assays, and target validation studies in mammalian cells, we show that tenovins act through inhibition of the protein-deacetylating activities of SirT1 and SirT2, two important members of the sirtuin family. Tenovins are active on mammalian cells at one-digit micromolar concentrations and decrease tumor growth in vivo as single agents. This underscores the utility of these compounds as biological tools for the study of sirtuin function as well as their potential therapeutic interest.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
抗 α-微管蛋白单克隆抗体 小鼠抗, clone DM1A, ascites fluid
Sigma-Aldrich
乙酰化微管蛋白单克隆抗体 小鼠抗, clone 6-11B-1, ascites fluid
Sigma-Aldrich
曲古抑菌素A, ≥98% (HPLC), from Streptomyces sp.
Sigma-Aldrich
抗乙酰组蛋白H4(Lys16)抗体, Upstate®, from rabbit
Sigma-Aldrich
抗组蛋白H4抗体, Upstate®, from rabbit